U.S. Markets close in 3 mins

Catabasis Pharmaceuticals, Inc. (CATB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7700-0.0100 (-0.56%)
As of 4:00PM EDT. Market open.

Catabasis Pharmaceuticals, Inc.

100 High Street
28th Floor
Boston, MA 02110
United States
617 349 1971

Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Ms. Jill C. MilneCo-Founder, CEO, Pres & Director716.96kN/A1968
Dr. Andrew J. NicholsChief Scientific Officer544.24kN/A1961
Mr. Noah Clauser CPAChief Financial OfficerN/AN/A1973
Mr. Benjamin S. Harshbarger J.D.Sr. VP & Gen. CounselN/AN/A1969
Ms. Keri McGrailSr. VP of HRN/AN/AN/A
Ms. Andrea L. MatthewsSr. VP of Corp. AffairsN/AN/AN/A
Mr. Andrew A. KomjathyChief Commercial OfficerN/AN/A1964
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

Corporate Governance

Catabasis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.